Pharmaceutical and Life Sciences
Search documents
WuXi AppTec Implements Its First Interim Dividend Plan, Distributing RMB1.03 Billion in Cash Dividends
Prnewswire· 2025-09-22 00:00
Accessibility StatementSkip Navigation SHANGHAI, Sept. 21, 2025 /PRNewswire/ -- WuXi AppTec Co., Ltd. (Stock Codes: 603259.SH/2359.HK), a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, implemented its first interim dividend plan, distributing a total of RMB1.03 billion in cash dividends. Also from this source WuXi AppTec Awarded Gold Medal by EcoVadis Sustainability Rating for Second Consecutive Year WuX ...
WuXi AppTec Provides Updates on Q2 Share Repurchase/Acquisition Activities
Prnewswire· 2025-07-08 02:41
Core Viewpoint - WuXi AppTec is actively enhancing shareholder value through A-share repurchase and H-share acquisition programs, aimed at attracting and retaining talent while maintaining company stability [1][2][3] A-Share Repurchase and Cancellation - The company repurchased and cancelled A-shares worth RMB1.0 billion to uphold its value and protect shareholder interests [2][3] - From April 18, 2025, to June 20, 2025, WuXi AppTec acquired 15,775,377 A-shares, approximately 0.55% of total issued share capital, at an average price of RMB63.39 per share [3] - The cancellation of all repurchased A-shares was completed on June 24, 2025 [3] H-Share Acquisition - WuXi AppTec instructed the Scheme Trustee to acquire HKD2.5 billion worth of H-shares to support the 2025 H Share Award and Trust Scheme [2][3] - A total of 34,092,975 H-shares were acquired, representing approximately 1.19% of total issued share capital, with no dilution to existing shareholders [3] - The H-share acquisition aims to attract and retain top talent, enhancing management capabilities and business resilience [3] H Share Award and Trust Scheme - Under the scheme, up to HKD1.5 billion worth of H-shares will be granted if the company's 2025 revenue reaches at least RMB42.0 billion [3] - An additional HKD1.0 billion worth of H-shares will be granted if the revenue reaches at least RMB43.0 billion, totaling HKD2.5 billion [3]